Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study

Affiliations

¹ Department of Neurology, University of Miami, 1120 NW 14th Street, Clinical Research Building, Room 1318, Miami, FL, 33136, USA. mbenatar@med.miami.edu.
² Department of Neurology, University of Miami, 1120 NW 14th Street, Clinical Research Building, Room 1318, Miami, FL, 33136, USA.
³ Department of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.
⁴ Washington University School of Medicine, St. Louis, MO, USA.
⁵ The Neurological Institute, Columbia University Irving Medical Center, New York, NY, USA.
⁶ Department of Neurology, Martin Luther University, Halle-Wittenberg, Halle (Saale), Germany.
⁷ Duke University School of Law, Durham, NC, USA.
⁸ Columbia University Irving Medical Center, New York, NY, USA.
⁹ Biogen, 225 Binney Street, Cambridge, MA, 02142, USA.
¹⁰ Biogen, 225 Binney Street, Cambridge, MA, 02142, USA. Stephanie.fradette@biogen.com.

Published Erratum

Michael Benatar et al. Neurotherapeutics. 2022 Sep.

. 2022 Sep;19(5):1686.

doi: 10.1007/s13311-022-01286-9.

¹ Department of Neurology, University of Miami, 1120 NW 14th Street, Clinical Research Building, Room 1318, Miami, FL, 33136, USA. mbenatar@med.miami.edu.
² Department of Neurology, University of Miami, 1120 NW 14th Street, Clinical Research Building, Room 1318, Miami, FL, 33136, USA.
³ Department of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.
⁴ Washington University School of Medicine, St. Louis, MO, USA.
⁵ The Neurological Institute, Columbia University Irving Medical Center, New York, NY, USA.
⁶ Department of Neurology, Martin Luther University, Halle-Wittenberg, Halle (Saale), Germany.
⁷ Duke University School of Law, Durham, NC, USA.
⁸ Columbia University Irving Medical Center, New York, NY, USA.
⁹ Biogen, 225 Binney Street, Cambridge, MA, 02142, USA.
¹⁰ Biogen, 225 Binney Street, Cambridge, MA, 02142, USA. Stephanie.fradette@biogen.com.

No abstract available

Erratum for

Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, Otto M, Farahany NA, Harrington EA, Chen W, Mitchell AA, Ferguson T, Chew S, Gedney L, Oakley S, Heo J, Chary S, Fanning L, Graham D, Sun P, Liu Y, Wong J, Fradette S. Benatar M, et al. Neurotherapeutics. 2022 Jul;19(4):1248-1258. doi: 10.1007/s13311-022-01237-4. Epub 2022 May 18. Neurotherapeutics. 2022. PMID: 35585374 Free PMC article. Clinical Trial.